Complaints of particulates found in vials of nine lots of Cubist Pharmaceuticals’ anti-infective drug Cubicin prompted the company to initiate its second recall of the drug in as many days.

The affected lots were distributed between July and December of last year. Although no adverse events have been reported, Cubist says particulates could potentially lead to a life-threatening embolism, blockage of capillaries or inflammatory responses.

This latest Cubicin recall comes on the heels of an Aug. 6 recall of 101 lots with possible glass particles stemming from an issue with a single production line that the company has since closed down.

While Cubist is still investigating the nature and source of the latest particulates, spokeswoman Julie DiCarlo said that none of the particulates appear to be glass and the company does not suspect that a manufacturing problem is the cause.

Anyone in possession of affected lots of the drug can contact Cubist to arrange to return the product and receive a replacement.

Cubicin (daptomycin injection) is indicated to treat certain skin and blood infections. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.